Fowble Barbara, Park Catherine, Wang Frederick, Peled Anne, Alvarado Michael, Ewing Cheryl, Esserman Laura, Foster Robert, Sbitany Hani, Hanlon Alex
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):634-41. doi: 10.1016/j.ijrobp.2015.02.031. Epub 2015 Apr 28.
Mastectomy rates for breast cancer have increased, with a parallel increase in immediate reconstruction. For some women, tissue expander and implant (TE/I) reconstruction is the preferred or sole option. This retrospective study examined the rate of TE/I reconstruction failure (ie, removal of the TE or I with the inability to replace it resulting in no final reconstruction or autologous tissue reconstruction) in patients receiving postmastectomy radiation therapy (PMRT).
Between 2004 and 2012, 99 women had skin-sparing mastectomies (SSM) or total nipple/areolar skin-sparing mastectomies (TSSM) with immediate TE/I reconstruction and PMRT for pathologic stage II to III breast cancer. Ninety-seven percent had chemotherapy (doxorubicin and taxane-based), 22% underwent targeted therapies, and 78% had endocrine therapy. Radiation consisted of 5000 cGy given in 180 to 200 cGy to the reconstructed breast with or without treatment to the supraclavicular nodes. Median follow-up was 3.8 years.
Total TE/I failure was 18% (12% without final reconstruction, 6% converted to autologous reconstruction). In univariate analysis, the strongest predictor of reconstruction failure (RF) was absence of total TE/I coverage (acellular dermal matrix and/or serratus muscle) at the time of radiation. RF occurred in 32.5% of patients without total coverage compared to 9% with coverage (P=.0069). For women with total coverage, the location of the mastectomy scar in the inframammary fold region was associated with higher RF (19% vs 0%, P=.0189). In multivariate analysis, weight was a significant factor for RF, with lower weight associated with a higher RF. Weight appeared to be a surrogate for the interaction of total coverage, thin skin flaps, interval to exchange, and location of the mastectomy scar.
RFs in patients receiving PMRT were lowered with total TE/I coverage at the time of radiation by avoiding inframammary fold incisions and with a preferred interval of 6 months to exchange.
乳腺癌的乳房切除术率有所上升,即刻乳房重建的比例也随之增加。对于一些女性而言,组织扩张器和植入物(TE/I)重建是首选或唯一的选择。这项回顾性研究调查了接受乳房切除术后放射治疗(PMRT)的患者中TE/I重建失败的发生率(即移除TE或I且无法进行替换,导致最终无法进行重建或采用自体组织重建)。
2004年至2012年间,99名患有病理分期为II至III期乳腺癌的女性接受了保留皮肤的乳房切除术(SSM)或保留乳头/乳晕全皮肤乳房切除术(TSSM),并即刻进行TE/I重建和PMRT。97%的患者接受了化疗(基于阿霉素和紫杉烷),22%的患者接受了靶向治疗,78%的患者接受了内分泌治疗。放疗包括对重建乳房给予5000 cGy,分180至200 cGy进行,锁骨上淋巴结可选择接受或不接受治疗。中位随访时间为3.8年。
TE/I重建完全失败率为18%(12%最终未完成重建,6%转换为自体组织重建)。在单因素分析中,重建失败(RF)的最强预测因素是放疗时TE/I没有完全覆盖(无细胞真皮基质和/或锯肌)。未完全覆盖的患者中RF发生率为32.5%,而完全覆盖的患者中为9%(P = 0.0069)。对于完全覆盖的女性,乳房切除疤痕位于乳房下皱襞区域与较高的RF相关(19%对0%,P = 0.0189)。在多因素分析中,体重是RF的一个重要因素,体重越低,RF越高。体重似乎是完全覆盖、薄皮瓣、更换间隔和乳房切除疤痕位置相互作用的一个替代指标。
接受PMRT的患者通过在放疗时实现TE/I完全覆盖、避免乳房下皱襞切口以及选择6个月的最佳更换间隔,可以降低RF。